Mon.Jun 02, 2025

article thumbnail

Common Barriers Inhibit Pneumococcal Vaccine Uptake Among Older Adults

Drug Topics

The most common barriers to vaccination included finances, logistics, availability of information, and hesitancy or refusal.

Vaccines 482
article thumbnail

CDC Clarifies That Kids May Receive COVID-19 Vaccine Through Shared Clinical Decision-Making

Pharmacy Times

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New report: Post-approval innovation delivers substantial patient benefits

PhRMA

Post-approval R&D is the continued investigation by biopharmaceutical companies, often through lengthy clinical trials, to find new uses and improvements for U.S. Food and Drug Administration (FDA)-approved medicines to better meet patient needs. Recently, there has been growing discussion among IP critics aimed at undermining the importance of post-approval R&D.

FDA 144
article thumbnail

Opinion: MAHA kids’ health report misinforms about tonsillectomies and ear tubes

STAT

The Make America Healthy Again commission’s recent report on children’s health has received a lot of attention for its citation errors and focus on ultra-processed foods, smartphones, and stimulant use. But the less-discussed part on “overmedicalization” of American children stood out to us. While the report mentions surgical care only briefly, it identifies two common procedures, adenotonsillectomy and tympanostomy tube (ear tube) placement, as surgeries that “

116
116
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

FDA Approves mRNA-1283 COVID-19 Vaccine for Adults 65 and Older, Those With Underlying Conditions

Pharmacy Times

Amid intensified scrutiny of COVID-19 vaccines at HHS, Modernas mRNA-1283 COVID-19 vaccine was granted FDA approval, for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk for severe COVID-19.

Vaccines 118
article thumbnail

STAT+: FDA plans to begin rolling out AI tool agency-wide on Tuesday

STAT

The Food and Drug Administration plans to roll out its agency-wide AI tool on Tuesday, weeks ahead of schedule, according to a press release obtained by STAT that provides the most detailed look yet at the technology and how it may be used. Commissioner Marty Makary has hailed the potential of the AI at the FDA, saying it could save employees time and ultimately speed up regulatory reviews.

FDA 130

More Trending

article thumbnail

Ingredient up to 13,000 times sweeter than sugar lurks in vapes popular with teens, study shows

STAT

Ice cream, lip gloss, and sparkling water are just a few of the products that can contain neotame — an artificial sweetener that’s 7,000-13,000 times sweeter than sugar. Now researchers have found it’s also in many flavored disposable e-cigarettes, which they warn gives them extra appeal to teens and kids. The study , published Monday in JAMA, found neotame in all 11 of the popular disposable vape brands it tested, including Elf Bar, Breeze, and Mr.

FDA 112
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

HIV and cancer prevention advocates are among the groups worried over cuts to critical programs at HHS under a new fiscal year 2026 budget request.

77
article thumbnail

STAT+: Bristol Myers to partner with BioNTech on experimental cancer drug

STAT

Bristol Myers Squibb said Monday it will pay the German firm BioNTech billions of dollars to split rights for an experimental cancer drug called BNT327, which works on both PD-L1, the target of blockbuster drugs Imfinzi and Tecentriq, and VEGF, the target of the blockbuster Avastin. A similar experimental antibody drug, from Summit Therapeutics and the Chinese firm Akeso, has garnered attention because it outperformed Merck’s Keytruda, the best-selling drug in the world, in a study in non

95
article thumbnail

UK shortage of critical drug forcing pancreatic cancer patients to skip meals

The Guardian - Pharmaceutical Industry

One pharmacist described scarcity of life-saving Creon as worst stock shortage they have dealt with People with pancreatic cancer are eating only one meal a day because of an acute shortage of a drug that helps them digest their food. Patients with cystic fibrosis and pancreatitis are also affected by the widespread scarcity of Creon , a form of pancreatic enzyme replacement therapy (PERT).

77
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent

STAT

Kymera Therapeutics on Monday reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial. The Phase 1 trial, which enrolled 118 healthy volunteers, tested the safety and tolerability of KT-621, a small molecule drug that targets STAT6, a signaling protein that plays a key role in driving immune activation.

article thumbnail

NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care

Pharmacy Times

Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug interactions.

123
123
article thumbnail

STAT+: Enhertu, used as first option, stalled tumors for more than a year in women with breast cancer, study finds

STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by well over a year in a group of women with a type of metastatic but previously untreated breast cancer — study results reported Monday that the drug’s makers AstraZeneca and Daiichi Sankyo believe could change the way the disease is treated for the first time in a decade.

77
article thumbnail

ASCO 2025: Informing Treatment Decisions Using a 14-Gene Assay in Early-Stage NSCLC

Pharmacy Times

A study reveals a 14-gene assay guides chemotherapy decisions effectively in patients with early-stage non-small cell lung cancer (NSCLC).

article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Opinion: Medicine warns doctors not to get too close. I’m glad mine did anyway

STAT

The morning of the procedure, Dr. Z greets me with uncharacteristic solemnity. “How are you feeling?” she asks, and I hear the question behind the question: How close is too close? For as long as I could remember, the hospital had been a second home. By age 5 I’d memorized the familiar litany: “Full name, date of birth, no allergies to food or medication.

article thumbnail

COVID’s remaining biotech contenders navigate a dwindling market

PharmaVoice

With policy and funding evolving, companies are being forced to rethink strategies.

130
130
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

The Coalition for Health AI (CHAI) has certified its first partnership for AI model validation, after a 16-month effort to get a nationwide network of AI assurance labs up and running.

63
article thumbnail

New Jersey Society of Health-System Pharmacy Hosts 2nd Annual Pharmacy Leader and Pharmacy Technician Symposium

Pharmacy Times

The NJSHP's 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding.

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

pharmaphorum

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data

66
article thumbnail

FDA Grants Interchangeability Designation to Hadlima, a Biosimilar for Humira

Pharmacy Times

The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions.

FDA 108
article thumbnail

Sanofi draws up $9.1bn plan to buy Blueprint Meds

pharmaphorum

Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM

100
100
article thumbnail

NCPA Fly-In Amplifies Pharmacists' Voice on Capitol Hill: Advocacy, Access, and the Fight for Fair Reimbursement

Pharmacy Times

National Community Pharmacists Association President Jeff Harrell, PharmD, shares insights from this years event, highlighting its growing impact, the importance of engaging with policymakers, and the urgent issues facing independent pharmacies

article thumbnail

Drugmaker Invidior to abandon London listing amid exodus of companies

The Guardian - Pharmaceutical Industry

Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year Business live latest updates The drugmaker Indivior has become the latest company to abandon its listing in London, heaping further pressure on the London Stock Exchange (LSE) to reinvigorate itself. The Virginia-based company, which makes the opioid addiction treatments Sublocade and Suboxone, switched its main stock listing to the US last year, but now plans to cancel the secondary li

54
article thumbnail

Winning with Healthcare Digital Marketing in 2025

Pharma Marketing Network

What if reaching the right patient or HCP at the perfect moment could be done in real timeat scale? Thats no longer a futuristic vision but a reality in 2025. Healthcare digital marketing has rapidly evolved from static display ads to dynamic, data-driven experiences that adapt to users’ behaviors and preferences. For pharma marketers, the stakes have never been higher.

HIPAA 52
article thumbnail

Rebuild Without Breaking Down: A New Blueprint for Your Life

Dr. Jamie Hardy: The Lifestyle Pharmacist

Youre halfway through the year, which makes now the ideal time to pause and ask yourself: Is the life Im building still aligned with the woman Im becoming? Now is the perfect time to create space to realign , refocus , and reclaim the parts of you that may have been buried under months of pushing, producing, and powering through. Its also important to remember that rebuilding doesnt mean scrapping everything and starting over from scratch.

52
article thumbnail

BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug

Pharmaceutical Technology

BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A.

88
article thumbnail

Fierce Healthcare - Untitled Article

Fierce Healthcare

Digital health company Scripta Insights is joining forces with RxSaveCard with the goal of making it easier for employers to manage drug costs and meet their fiduciary duties.

51
article thumbnail

ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

Pharmaceutical Technology

MSDs investigational KRASG12C inhibitor has shown signs of anti-tumour activity when used both alone and with other oncology drugs.

52
article thumbnail

The Hidden Risks in RPM Billing: What Every US Healthcare Practice Should Know in 2025

PharmD Live

RPM’s Booming Promise and Its Perils Remote patient monitoring (RPM) is not just a trend but a core pillar of modern US healthcare. By 2025, over 71 million Americans (26% of the population) are expected to use RPM services, with the US market projected to double to $29+ billion by 2030. RPM delivers proven clinical benefits: reducing hospital admissions by 38% and ER visits by 51% , with patient satisfaction exceeding 90%.

article thumbnail

Supercharging clinical trials with data and AI: Realyze’s Aaron Brauser on faster, smarter design

pharmaphorum

Supercharging clinical trials with data and AI: Realyzes Aaron Brauser on faster, smarter design Mike.

52
article thumbnail

ASCO 2025: Quadruplet Therapy Shows Promise in Transplant-Ineligible Multiple Myeloma

Pharmacy Times

Saad Usmani, MD, MBA, FACP, FASCO, discusses the subgroup analysis of transplant-ineligible (TIE) patients with newly diagnosed multiple myeloma (NDMM) from the CEPHEUS trial.

81
article thumbnail

BioNTech flips its cancer bispecific to BMS for a big profit

pharmaphorum

Bristol Myers Squibb is spending big to avoid being left behind in the race to develop a much-touted class of bispecific antibodies for cancer

69
article thumbnail

STAT+: On ASCO Day 4, J&J bets on Rybrevant and airs ‘innovation ecosystem’ concerns

STAT

This is the web version of STAT’s  special newslette r from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter  here. ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year.

46